 Atlanta, Georgia--Newsfile Corp. - July 6, 2021 - Holzer Holzer, LLC is investigating whether Provention Bio, Inc. Provention or the Company NASDAQ: PRVB complied with federal securities laws. On July 6, 2021, Provention announced the issuance of a Complete Response Letter CRL by the FDA for the Companys Biologics License Application BLA for the drug Teplizumab. Specifically, the FDA noted that a recent study failed to show Pharmacokinetic comparability and notified Provention that... 